Biogen announced an exclusive global license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front with up to $990 million in potential milestones. Jane Grogan, Biogen’s head of research, said the deal advances the company’s immunology strategy by targeting innate immune signaling. Biogen will lead development, manufacturing and commercial work; Vanqua retains resources to focus on its neuroscience programs. The agreement accelerates a large pharma’s move into complement and C5aR1-directed therapies, a well‑validated axis in inflammatory disease.